Skip to main content

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.

Overview

Overview

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Key Inclusion Criteria

Key Inclusion Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.

  1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICFs and in the protocol.
  2. Age ≥18 years at the time of screening (ICF1);
  3. Histologically confirmed NSCLC with resectable stage II-III disease
  4. Complete resection of the primary NSCLC
Key Exclusion Criteria

Key Exclusion Criteria

  • EGFR and/or ALK mutant
  • Mixed small cell and NSCLC histology
  • History of allogeneic organ or bone marrow transplantation
  • History of active primary immunodeficiency
Learn More

Learn More

To learn more, visit ClinicalTrials.Gov

Study Type

Phase III

Principal Investigator(s)

Vikas Dembla, MD

Sponsor(s)

AstraZeneca

Contact Us

Contact Us

To participate in this study, please contact Sue Stanley, RN at
864-560-7252